Cannabidiol Therapy, EHP-101, Put on Fast Track by FDA
EHP-101, an oral therapy based on cannabidiol (CBD), has been placed on fast track development by the U.S. Food and Drug Administration (FDA) as a potential treatment of systemic…
Steve Bryson, PhD, science writer—
Articles by Steve Bryson
Model Identifies Five Skin-Score Classes to Predict Systemic Sclerosis Progression
A statistical model applied to a widely used measure of skin thickening in people newly diagnosed with systemic sclerosis (SSc) identified five classes that may predict organ involvement and survival rates. Using these predictive classes — based on the…
Immune Dendritic Cells are Potential Therapeutic Target in Scleroderma, Mouse Study Suggests
Immune players known as dendritic cells play a key role in scleroderma development in the skin and may represent a new target for effective treatments, a mouse study suggests. The study, “Regulation of skin fibrosis by RALDH1-producing dermal dendritic cells via…
Localized Scleroderma Affects Quality of Life in Children, Study Finds
Localized scleroderma affects health-related quality of life (HRQoL) in young people, causing joint and muscle pain, putting limits on physical activity, and hurting body image, a study found. Teasing from peers, unwanted questions from others, and side effects from treatment were…
Groups of Genes Linked with Scleroderma in Different Tissues, DNA Analysis Finds
A large-scale DNA analysis in different tissues revealed an association between scleroderma and groups of genes driving well-known inflammation pathways. This approach helps explain the complex interplay between the diverse genes associated with scleroderma development. It also shows potential to lead to targeted and effective therapies, the investigators…
Galapagos Completes Enrollment in Phase 2a Trial Testing GLPG1690 in Diffuse Cutaneous Scleroderma
A Phase 2a clinical trial designed to test Galapagos‘ investigational oral therapy GLPG1690 in people with diffuse cutaneous scleroderma has completed enrolling participants, the company announced. GLPG1690 is a small molecule that targets and blocks autotaxin. This enzyme…
Lenabasum Shows Sustained Efficacy in Patients with Diffuse Cutaneous Scleroderma, Extension Study Finds
People with diffuse cutaneous scleroderma (dcSSc) being treated with lenabasum continue to show improvement after more than two years of the therapy, an update from a Phase 2 extension study shows. The research, “…
Digital Ulcers Strongly Affect Pain and Daily Life in Scleroderma Patients, Spanish Study Finds
Digital ulcers (DUs) aggravate hand disability, limit daily activities, and affect work productivity in people with scleroderma, a real-world study from Spain reports. Patients with DUs had more pain, a higher incidence of Raynaud’s phenomenon, and reported having…
Early Immunosuppressive Treatment May Prevent ILD Progression in SSc Patients, Study Suggests
Immunosuppressive treatment of early-stage interstitial lung disease (ILD) in people with systemic sclerosis may be a potential therapeutic option to prevent ILD progression, a study suggests. The study, “Association between immunosuppressive therapy and course of mild interstitial lung disease…
Specific Autoantibody Protects Some SSc Patients Against Cancer, Study Suggests
Some people with systemic sclerosis (SSc) are protected from cancer development by the presence of anti-RNA polymerase I autoantibodies, a study suggests. The study, “Scleroderma patients with antibodies against the large subunits of both…